Pipeline
Ciloa's multi-purpose technology allows to develop a pipeline of therapeutic and preventive applications
Our EVENGI sEV bioengineering and bioproduction platform is designed to help develop a new generation of biotherapeutics. The most advanced are those concerning metabolic diseases and also vaccines against emerging viruses. The next applications are in the oncology field for which sEV biotherapeutic candidates are in development.
Therapeutic sEV Pipeline
APN-sEV biotherapeutics
Having overcome the challenge of producing stable and functional recombinant APN, Ciloa is now well-placed to develop APN-sEV drug candidates for several major diseases, with the first being for obesity, type 2 diabetes and MASH.
Candidates in Cardiovascular diseases and retinopathies will come soon.
Oncology
The ability to incorporate any ligand that can specifically target certain tumours, in combination with various cargoes (some of which are toxic), paves the way for the development of sEV biotherapeutic candidates in oncology. Different targets and means of selectively inducing tumour cell death are currently being evaluated, with very promising initial results.
Vaccines Pipeline
Ciloa bioengineering technology enables us to graft any viral envelope glycoprotein onto the surface of sEVs. We have developed vaccine candidates comprising mature, multimerised viral glycoproteins which are indistinguishable from mature virions when it comes to the recognition of specific antibodies. These vaccines trigger strong immune responses. We were able to analyse the immune responses of some of these vaccines in terms of neutralising antibodies, cytotoxic T-cell responses and protection against viral challenge.
Example of SARS-CoV-2 neutralisation capacity of CoVEVax vaccine
Spike displayed on sEVs is an efficient pan SARS-CoV-2 vaccine
Spike-sEVs : Neutralisation titers obtained after 2 injections of DNA coding for Spike presented on sEVs thanks to its fusion to the Pilot Peptide + 1 boost of pure sEVs harboring Spikes
Spike : Neutralisation titers obtained after 3 injections of DNA coding for regular spike without the Pilot Peptide.